Is Rite Aid Corporation Destined for Greatness?

Let's see what the numbers say about Rite Aid.

Jun 2, 2014 at 9:35AM

Investors love stocks that consistently beat the Street without getting ahead of their fundamentals and risking a meltdown. The best stocks offer sustainable market-beating gains, with robust and improving financial metrics that support strong price growth. Does Rite Aid Corporation (NYSE:RAD) fit the bill? Let's take a look at what its recent results tell us about its potential for future gains.

What we're looking for
The graphs you're about to see tell Rite Aid's story, and we'll be grading the quality of that story in several ways:

  • Growth: Are profits, margins, and free cash flow all increasing?
  • Valuation: Is share price growing in line with earnings per share?
  • Opportunities: Is return on equity increasing while debt to equity declines?
  • Dividends: Are dividends consistently growing in a sustainable way?

What the numbers tell you
Now, let's take a look at Rite Aid's key statistics:

RAD Total Return Price Chart

RAD Total Return Price data by YCharts.

Passing Criteria

3-Year* Change


Revenue growth > 30%



Improving profit margin



Free cash flow growth > Net income growth

34.2% vs. 144.9%


Improving EPS



Stock growth (+ 15%) < EPS growth

478.6% vs. 127.7%


Source: YCharts. *Period begins at end of Q1 2011.

RAD Return on Equity (TTM) Chart

RAD Return on Equity (TTM) data by YCharts.

Passing Criteria

3-Year* Change


Improving return on equity



Declining debt to equity



Source: YCharts. *Period begins at end of Q1 2011.

How we got here, and where we're going
Rite Aid's score has cratered since last year, as the pharmacy chain earns only two out of seven possible passing grades today, down from four in 2013. Rite Aid's net income growth has outpaced the gains in its free cash flow, but even a doubling of EPS in three years falls far short of the near-six-bagger returns Rite Aid investors have enjoyed -- virtually all of which has happened in the final two of those three years. Moreover, Rite Aid's negative return on equity and the massive debt on its balance sheet also continue to affect its performance. Rite Aid has been on the right track, but can it actually justify investor optimism with equally impressive fundamental growth in the coming quarters? Let's dig a little deeper to find out.

Rite Aid posted market-topping revenue and earnings per share in its fiscal fourth quarter despite the inclement weather that hammered much of the United States this past winter. The company also reported an impressive 5% increase in same-store sales for the month of April, although this seems to be due largely to the timing of Easter celebrations this year. Ride Aid also made a surprise move to acquire RediClinic, an operator of 30 retail mini-clinics in several Texan cities, and it now plans to grow the clinic by another 70 locations by the end of 2015. Rite Aid and its peers should also continue to benefit from higher-margin generic drug sales, as pharmaceutical companies are in the process of falling off a patent cliff, losing patent protections on drugs accounting for $123 billion in global sales between 2012 and 2017.

Rite Aid's shares have already rallied more than 50% this year as the company continues to implement its strategic growth plan, which emphasizes closing unprofitable stores while remodeling and relocating more viable ones, which has allowed it to dramatically improve its fundamentals over the past few years. Rite Aid seems to deserve a better valuation than it now boasts relative to larger peers Walgreen (NASDAQ:WBA) and CVS Caremark (NYSE:CVS) -- Rite Aid currently trades at a low 0.3 price-to-sales ratio, compared to Walgreen's 0.9 and CVS Caremark's 0.7 price-to-sales ratios. However, weaker profit margins than its fellow pharmacy chains likely hold Rite Aid back from this higher valuation, as you'll see below:

RAD PS Ratio (TTM) Chart

RAD PS Ratio (TTM) data by YCharts.

Fool writer Andres Cardenal points out that Rite Aid has converted more than 1,200 stores to its updated "wellness" format, and will close in on 1,600 remodeled stores by the end of the year. Rite Aid has also enrolled over 1.7 million elderly consumers in its Wellness 65+ loyalty program, which cleverly targets the segment of the populace most dependent on pharmacy sales and services. Rite Aid has also expanded its generic-drug sourcing and distribution agreement as part of McKesson's (NYSE:MKC) One Stop proprietary generics program, which should reduce purchasing costs and working capital needs by $150 million over the next fiscal year. That's no small accomplishment, as $150 million is a full 60% of Rite Aid's trailing-12-month profit. However, Walgreen's sourcing partnership with AmerisourceBergen offers a vast network of 170,000 distribution points, and its acquisitions of USA Drug and Kerr Drug last year further enhance its reach. Meanwhile, CVS continues to expand its in-store MinuteClinic franchises, which currently add up to more than 800 locations in the U.S.

Putting the pieces together
Today, Rite Aid has few of the qualities that make up a great stock, but no stock is truly perfect. Digging deeper can help you uncover the answers you need to make a great buy -- or to stay away from a stock that's going nowhere.

Will this stock be your next multi-bagger?
Give us five minutes, and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year, his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252%, and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Alex Planes has no position in any stocks mentioned. The Motley Fool recommends CVS Caremark. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information